MoonLake Immunotherapeutics AG — Sponsor Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

7 Recruiting

6 Completed trials

22 Countries active

7 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (FiH)

Phase III: 8 Phase II: 3 Phase I: 1 Phase I (FiH): 2

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Lymphoma 1

Top IMPs

SONELOKIMAB 9 AUTOLOGOUS T-CELLS EX VIVO MODIFIED WITH A LENTIVIRAL VECTOR ENCODING A CHIMERIC ANTIGEN RECEPTOR SPECIFIC FOR CD1A 2 MPS-112, MPS-106, MPS-213, MPS-102, MPS-216, MPS-103, MPS-215, MPS-214, D-ALA-LYS-CHA-VAL-ALA-ALA-TRP-THR-LEU-LYS-ALA-ALA-D-ALA, MPS-200 2 (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE 1 IMSIDOLIMAB 1 RISANKIZUMAB 1

All trials

14 total

A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 Phase III 16 countries SONELOKIMAB
Long-term Follow-up study for relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) patients previously treated … Recruiting

2024-516617-20-00 Phase III 1 country AUTOLOGOUS T-CELLS EX VIVO MODIFIED WITH A LENTIVIRAL VECTOR ENCODING A CHIMERIC…
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Phase III 13 countries SONELOKIMAB
A Phase 2, open-label, imaging study to explore the effects of sonelokimab in patients with active psoriatic arthritis or axial spondyloarth… Recruiting

2024-514504-13-00 Phase II 1 country (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting

2024-516219-25-00 Phase III 7 countries RISANKIZUMAB; SONELOKIMAB
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting

2023-509340-10-00 Phase III 11 countries MPS-112, MPS-106, MPS-213, MPS-102, MPS-216, MPS-103, MPS-215, MPS-214, D-ALA-LY…
Safety and efficacy of hCD1a-CAR T (OC-1) therapy, in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (… Recruiting

2024-514591-40-00 Phase I 1 country AUTOLOGOUS T-CELLS EX VIVO MODIFIED WITH A LENTIVIRAL VECTOR ENCODING A CHIMERIC…
A multicenter phase 1/2 study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas Recruiting

2024-514826-22-00 Phase I (FiH) 3 countries IMSIDOLIMAB; MPS-112, MPS-106, MPS-213, MPS-102, MPS-216, MPS-103, MPS-215, MPS-…
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Phase III 16 countries SONELOKIMAB
A Phase 2 open-label imaging study to explore the effects of sonelokimab in patients with active axial spondyloarthritis Ended

2024-513498-36-00 Phase II 1 country SONELOKIMAB
A Phase 2, multicentre, open-label study of sonelokimab in patients with moderate-to-severe pustulosis palmoplantaris Ended

2024-513305-32-00 Phase II 1 country SONELOKIMAB
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended

2024-511360-87-00 Phase III 8 countries SONELOKIMAB
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended

2024-511363-28-00 Phase III 10 countries SONELOKIMAB
An phase I study of BI 765063 (a monoclonal antibody) as single agent and in combination with BI 754091 (a PD-1) to characterize safety, pha… Ended

2024-519150-37-00 Phase I (FiH) 1 country

Showing 1–14 of 14 trials

← All sponsors A–Z